Summit Therapeutics Inc. — Operating Income by Fiscal Year
8 fiscal years, as filed with the SEC; every row links its evidence fact.
Cite as: FACTANKER, https://factanker.com/entity/1f1205d0-d706-4a69-8ccd-b0fd75927244/serie/operating-income
| Fiscal year | Operating Income | Period | Evidence |
|---|---|---|---|
| FY 2024 | $-226.0M | 2024-01-01 – 2024-12-31 | evidence 0001599298-25-000048 |
| FY 2023 | $-609.6M | 2023-01-01 – 2023-12-31 | evidence 0001599298-24-000031 |
| FY 2022 | $-72.1M | 2022-01-01 – 2022-12-31 | evidence 0001599298-23-000034 |
| FY 2021 | $-86.2M | 2021-01-01 – 2021-12-31 | evidence 0001599298-22-000032 |
| FY 2020 | $-53.2M | 2020-01-01 – 2020-12-31 | evidence 0001599298-21-000011 |
| FY 2019 | $-27.5M | 2019-02-01 – 2019-12-31 | evidence 0001599298-21-000011 |
| FY 2018 | $5.4M | 2018-02-01 – 2019-01-31 | evidence 0001599298-21-000011 |
| FY 2017 | $-28.4M | 2017-02-01 – 2018-01-31 | evidence 0001599298-20-000039 |
Methodology & sources
One value per fiscal year (period > 300 days, latest period end per year); fiscal years ending Jun–Dec count toward the ending calendar year, Jan–May toward the prior year. Values as filed (XBRL concept per evidence fact). Source: SEC EDGAR (public domain).
One value per fiscal year (period > 300 days, latest period end per year); fiscal years ending Jun–Dec count toward the ending calendar year, Jan–May toward the prior year. Values as filed (XBRL concept per evidence fact). Source: SEC EDGAR (public domain).